Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Drug-drug Interaction,SHR3680 1

Interventions

Specimen Handling 49pembrolizumab 44Magnetic Resonance Spectroscopy 37Biopsy 35Cyclophosphamide 33fludarabine 28Cetuximab 20Cisplatin 19Carboplatin 19Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Fluorouracil 14fludarabine phosphate 13Radiotherapy 13Leucovorin 13Nivolumab 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Cytarabine 11Irinotecan 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Immunoglobulin G 9Fulvestrant 9durvalumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Rosuvastatin Calcium × 30 days × Clear all
NCT02592317 2026-06-05

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

Phase 1 Active not recruiting
23 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04621669 2026-06-05

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled

Drug-drug Interaction,SHR3680

Data powered by HemOnc (CC BY 4.0) Colophon âš¡